Joshua M. Lang

TL;DR: The NCCN Guidelines for Prostate Cancer address staging and risk assessment after a prostate cancer diagnosis and include management options for localized, regional, and metastatic disease Recommendations for disease monitoring and treatment of recurrent disease are also included as mentioned in this paper.

TL;DR: The potential reversal of immunosuppression by epigenetic modulation is therefore a promising and versatile therapeutic approach to reinstate endogenous immune recognition and tumor lysis.

TL;DR: This study identifies genomic regions that are differentially methylated during disease progression and a novel epigenomic subtype and shows that differential methylation during progression preferentially occurs at somatic mutational hotspots and putative regulatory regions.

TL;DR: Results suggest that repeated administration of IL-2 and ZA, at the doses and schedules used in this trial, may actually inhibit the proliferative capacity of Vγ9 Vδ2 T cell in patients with metastatic RCC.

TL;DR: AR-V9 was frequently coexpressed with AR-V7 and may be an important component of therapeutic resistance in CRPC, and both AR variant species were found to share a common 3′ terminal cryptic exon, which rendered AR-v9 susceptible to experimental manipulations that were previously thought to target AR- V7 uniquely.